Combination therapy for high-risk upper urinary tract cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of urinary tract cancer called urothelial carcinoma, confirmed by biopsy or other testing.
- Your tumor must be considered high-risk (for example, large size, muscle-invasive, or involves lymph nodes).
- Your cancer cells must show HER2 protein at a 1+ to 3+ level (a specific marker on the cells).
- You must be willing to have surgery and follow the treatment plan.
- You should not have cancer that has spread to distant organs or other serious medical conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Urothelial Carcinoma of the Renal Pelvis and Ureter trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.